Karen Zaderej Net Worth

The estimated Net Worth of Karen L. Zaderej is at least $3.64 Milione dollars as of 19 August 2024. Ms. Zaderej owns over 12,500 units of Axogen stock worth over $219,120 and over the last 13 years she sold AXGN stock worth over $2,416,191. In addition, she makes $999,963 as Chairman of the Board, President e Chief Executive Officer at Axogen.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Zaderej AXGN stock SEC Form 4 insiders trading

Karen has made over 36 trades of the Axogen stock since 2011, according to the Form 4 filled with the SEC. Most recently she bought 12,500 units of AXGN stock worth $99,750 on 19 August 2024.

The largest trade she's ever made was exercising 175,000 units of Axogen stock on 2 August 2018 worth over $479,500. On average, Karen trades about 18,722 units every 70 days since 2011. As of 19 August 2024 she still owns at least 16,500 units of Axogen stock.

You can see the complete history of Ms. Zaderej stock trades at the bottom of the page.

Karen Zaderej biography

Karen L. Zaderej serves as Chairman of the Board, President, Chief Executive Officer of the Company. She has served as Axogen’s President, Chief Executive Officer, a member of our board of directors (the “Board of Directors”) since September 2011 and became the Chairman of our Board of Directors in May 2018. She has served as the Chief Executive Officer of Axogen, and a member of Axogen’s board of directors since May 2010. Ms. Zaderej joined Axogen in May 2006 and served as Vice President of Marketing and Sales from May 2006 to October 2007 and as Chief Operating Officer from October 2007 to May 2010. From October 2004 to May 2006, Ms. Zaderej worked for Zaderej Medical Consulting, a consulting firm she founded, which assisted medical device companies in building and executing successful commercialization plans. From 1987 to 2004, Ms. Zaderej worked at Ethicon, Inc., a Johnson & Johnson company, where she held senior positions in marketing, business development, and research & development, as well as ran a manufacturing business. Ms. Zaderej is a Director of Viveve Medical, Inc., a public women's intimate health company. Ms. Zaderej has a MBA from the Kellogg Graduate School of Business and a BS in Chemical Engineering from Purdue University.

What is the salary of Karen Zaderej?

As the Chairman of the Board, President e Chief Executive Officer of Axogen, the total compensation of Karen Zaderej at Axogen is $999,963. There are 1 executives at Axogen getting paid more, with Eric Sandberg having the highest compensation of $1,113,440.

How old is Karen Zaderej?

Karen Zaderej is 58, she's been the Chairman of the Board, President e Chief Executive Officer of Axogen since 2018. There are 7 older and 7 younger executives at Axogen. The oldest executive at Axogen Inc. is Guido Neels, 71, who is the Independent Director.

What's Karen Zaderej's mailing address?

Karen's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.

Insiders trading at Axogen

Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels e Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.

What does Axogen do?

it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.

Complete history of Ms. Zaderej stock trades at Axogen, Viveve Medical Inc e EyePoint Pharmaceuticals Inc

Axogen executives and stock owners

Axogen executives and other stock owners filed with the SEC include:

• Eric Sandberg,
  Chief Commercial Officer
• Karen Zaderej,
  Chairman of the Board, President, Chief Executive Officer
• Gregory Freitag,
  Director
• Angelo Scopelianos,
  Vice President - Research and Development
• Peter Mariani,
  Chief Financial Officer
• Maria Martinez,
  Chief Human Resource Officer
• Quentin Blackford,
  Independent Director
• Alan Levine,
  Independent Director
• Amy Wendell,
  Lead Independent Director
• Mark Gold,
  Independent Director
• Guido Neels,
  Independent Director
• Paul Thomas,
  Director
• Brad Ottinger,
  Chief Compliance Officer, General Counsel
• Isabelle Billet,
  Chief Strategy and Business Development Officer
• Mark Friedman,
  Vice President - Regulatory Affairs and Quality Assurance
• Erick DeVinney,
  Vice President - Clinical and Translational Sciences
• Mike Donovan,
  Vice President - Operations
• James E Deerfield Mgmt L.P....,
  
• John P Engels,
  Vice President
• Jamie Mark Grooms,
  Director
• Robert James Rudelius,
  Director
• Joseph M Mandato,
  Director
• Shawn F Mccarrey,
  SVP of Sales
• Lisa N Colleran,
  Director
• Jon S. Gingrich,
  Chief Commercial Officer
• Woodlands Fund Ix, L.P. Essex,
  10% owner
• Kevin Leach,
  Vice President Marketing
• Kathy Johnson Weiler,
  Director
• William P. Mr. Burke,
  Director
• Lee Robert Jr Johnston,
  Chief Financial Officer
• Jill F Schiaparelli,
  SVP, Bus. Strategy&Marketing
• John Frederick Harper,
  Director
• Bradley Jay Hedger,
  Vice President, Sales
• David K Hansen,
  VP Finance & Treasurer
• Michael Patrick Donovan,
  VP Operations
• Joseph A. Tyndall,
  Director
• John Johnson,
  Director
• Nir Naor,
  CFO
• Marc A Began,
  EVP and General Counsel
• Jens Kemp,
  Chief Marketing Officer
• Michael D Dale,
  CEO and President